DHA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：本研究的主要目的是通过ADAS-Cog和CDR-SOB评分的变化，确定长期补充二十二碳六烯酸是否可以延缓轻中度阿尔茨海默病患者18个月内认知和功能下降的进展。 目的：(1)通过ADAS-COG和CDR-SOB评分的变化，确定长期补充DHA是否可以减缓轻中度AD患者18个月内认知和功能下降的进展；(2)使用经过验证的这些机制的生物标记物，确定长期补充DHA是否具有抗淀粉样蛋白、抗氧化或神经保护作用；(3)确定长期补充DHA对AD患者血浆和尿液氧化损伤生物标记物的影响。还将确定生物标记物和临床病程之间的关系，以确定这些可获得的生物标记物在临床试验中是否具有有用的作用；(4)确定其他相关微量营养素对AD临床病程的影响，以及对补充DHA的临床病程的反应

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: The primary objective of this study is to determine whether chronic docosahexaenoic acid (DHA) supplementation slows the progression of cognitive and functional decline over 18 months in mild to moderate Alzheimer s disease (AD), as indicated by change in scores on the ADAS-Cog and CDR-SOB. Aims: (1) To determine whether chronic DHA supplementation slows the progression of cognitive and functional decline over 18 months in mild to moderate AD, as indicated by change in scores on ADAS-cog and CDR-SOB; (2) To determine if chronic DHA supplementation exerts anti-amyloid, antioxidant, or neuroprotectant effects, using validated biomarkers of these mechanisms; (3) To determine the effects of chronic DHA supplementation on plasma and urine biomarkers of oxidative damage in AD. The relationship between the biomarker and clinical course will also be determined in order to establish whether these accessible biomarkers have a useful role in clinical trials; (4) To determine the effects of other relevant micronutrients on the clinical course of AD, and on the response of the clinical course to DHA supplementation